let’s discuss what people think of the new collaboration and new development of the other drug, is it the right time in the company for capital allocation given we are basically pre revenue and not commercial with spontan?
I like the diversification but is the timing right, what part are we playing in this collaboration, providing the tech?
are we attempting to run before we crawl, what is our alternative sit on our hands until tga and fda approval?
thoughts?
let’s discuss what people think of the new collaboration and new...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.020(6.45%) |
Mkt cap ! $32.46M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $199.8K | 680.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 58285 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 3162 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| LTP (ASX) Chart |